Cost of Praluent PCSK9 Inhibitor Lowered for Medicare Patients

The cost of Praluent, regardless of dose, will be $5,850 annually, a 60% reduction from the original price.

FEBRUARY 12, 2019

Most Insurers Denying Claims for PCSK9 Inhibitors

PCSK9 inhibitors, such as Repatha and Praluent have been shown to reduce low-density lipoprotein by 60% and ...

NOVEMBER 29, 2017

FDA Approves Once-Monthly Dosing Option for Praluent

Alirocumab, a PCSK9 inhibitor, is indicated as an adjunct to diet and maximally tolerated statin therapy for the ...

APRIL 26, 2017

Amgen Wins Next Step in Patent Dance Over PCSK9 Drugs

Despite the win, the case is long from over; Sanofi and Regeneron plan to appeal.

MARCH 24, 2016